KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 65 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $296,508 | +17.3% | 30,790 | +9.6% | 0.01% | +16.7% |
| Q2 2023 | $252,882 | +14.5% | 28,098 | 0.0% | 0.01% | +20.0% |
| Q1 2023 | $220,850 | -9.9% | 28,098 | +100.2% | 0.01% | -28.6% |
| Q3 2021 | $245,000 | -39.4% | 14,036 | -16.7% | 0.01% | -46.2% |
| Q2 2021 | $404,000 | -52.2% | 16,856 | -48.7% | 0.01% | -59.4% |
| Q1 2021 | $845,000 | -60.8% | 32,875 | -71.0% | 0.03% | -60.0% |
| Q4 2020 | $2,156,000 | +29.9% | 113,533 | -13.9% | 0.08% | -20.0% |
| Q3 2020 | $1,660,000 | +9.9% | 131,822 | +5.5% | 0.10% | -2.9% |
| Q2 2020 | $1,511,000 | +82.0% | 124,902 | +15.1% | 0.10% | +49.3% |
| Q1 2020 | $830,000 | +6.5% | 108,492 | +148.0% | 0.07% | +1.5% |
| Q4 2019 | $779,000 | +125.1% | 43,749 | +46.7% | 0.07% | +112.5% |
| Q3 2019 | $346,000 | +137.0% | 29,825 | +37.7% | 0.03% | +33.3% |
| Q3 2017 | $146,000 | -8.2% | 21,665 | 0.0% | 0.02% | -27.3% |
| Q2 2017 | $159,000 | -5.9% | 21,665 | 0.0% | 0.03% | +6.5% |
| Q1 2017 | $169,000 | +45.7% | 21,665 | +32.5% | 0.03% | +19.2% |
| Q4 2016 | $116,000 | – | 16,346 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $38,088,000 | 25.57% |
| VHCP Management III, LLC | 637,884 | $14,129,000 | 6.60% |
| Vivo Capital, LLC | 1,359,149 | $30,105,000 | 2.82% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $8,611,000 | 2.78% |
| VHCP Management II, LLC | 376,889 | $8,348,000 | 2.63% |
| Samsara BioCapital, LLC | 118,500 | $2,625,000 | 1.73% |
| ACUTA CAPITAL PARTNERS, LLC | 213,000 | $4,718,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 187,599 | $4,165,000 | 1.54% |
| Ghost Tree Capital, LLC | 300,000 | $6,645,000 | 1.38% |
| Eventide Asset Management | 1,500,000 | $33,225,000 | 1.01% |